AVALO THERAPEUTICS INC (AVTX) — insider trading
Health Care · NASDAQ
AVALO THERAPEUTICS INC (AVTX) has 103 reported SEC Form 4 insider transactions in our data, including 34 open-market sales among the most recent 100 (latest 2026-09-30).
Recent Form 4 transactions
Showing the 100 most recent of 103 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Philip Ron M | Director | Grant / award / vesting (derivative) | 1,109 | $12.29 | $13.6K | Form 4 |
| 2026-09-30 | Jain Rita | Director | Grant / award / vesting (derivative) | 1,322 | $12.29 | $16.2K | Form 4 |
| 2026-09-30 | Lind Kevin Robert | Director | Grant / award / vesting (derivative) | 1,352 | $12.29 | $16.6K | Form 4 |
| 2026-09-16 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 12,394 | — | $0 | Form 4 |
| 2026-09-16 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 12,394 | $16.33 | $202.4K | Form 4 |
| 2026-09-16 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion | 12,394 | $9.88 | $122.5K | Form 4 |
| 2026-09-10 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 10,185 | — | $0 | Form 4 |
| 2026-09-10 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 10,185 | $17.62 | $179.5K | Form 4 |
| 2026-09-10 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion | 10,185 | $8.04 | $81.9K | Form 4 |
| 2026-08-28 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 679 | — | $0 | Form 4 |
| 2026-08-28 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 679 | $20.00 | $13.6K | Form 4 |
| 2026-08-28 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 679 | $8.04 | $5.5K | Form 4 |
| 2026-08-18 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 31,031 | — | $0 | Form 4 |
| 2026-08-18 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 31,031 | $20.05 | $622.3K | Form 4 |
| 2026-08-18 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion | 31,031 | $9.88 | $306.6K | Form 4 |
| 2026-08-17 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-08-17 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 1,000 | $20.00 | $20.0K | Form 4 |
| 2026-08-17 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 1,000 | $12.65 | $12.7K | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 2,876 | — | $0 | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 37,945 | — | $0 | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 3,749 | $19.94 | $74.8K | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 37,945 | $19.85 | $753.3K | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion | 2,876 | $9.88 | $28.4K | Form 4 |
| 2026-08-17 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion | 37,945 | $9.88 | $374.9K | Form 4 |
| 2026-08-11 | Riley Jennifer | Officer (Chief Strategy Officer) | Open-market sale | 2,655 | $19.59 | $52.0K | Form 4 |
| 2026-08-10 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 679 | — | $0 | Form 4 |
| 2026-08-10 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 679 | $20.00 | $13.6K | Form 4 |
| 2026-08-10 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 679 | $8.04 | $5.5K | Form 4 |
| 2026-07-27 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-07-27 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 1,000 | $20.00 | $20.0K | Form 4 |
| 2026-07-27 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 1,000 | $12.65 | $12.7K | Form 4 |
| 2026-06-30 | Jain Rita | Director | Grant / award / vesting (derivative) | 1,080 | $15.04 | $16.2K | Form 4 |
| 2026-06-30 | Lind Kevin Robert | Director | Grant / award / vesting (derivative) | 1,105 | $15.04 | $16.6K | Form 4 |
| 2026-06-30 | Philip Ron M | Director | Grant / award / vesting (derivative) | 69 | $15.04 | $1.0K | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 1,779 | — | $0 | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 2,875 | — | $0 | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 4,654 | $20.00 | $93.1K | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 1,779 | $8.04 | $14.3K | Form 4 |
| 2026-06-30 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 2,875 | $12.65 | $36.4K | Form 4 |
| 2026-06-23 | Philip Ron M | Director | Grant / award / vesting (derivative) | 40,200 | — | $0 | Form 4 |
| 2026-06-23 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 1,450 | — | $0 | Form 4 |
| 2026-06-23 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 1,450 | $18.00 | $26.1K | Form 4 |
| 2026-06-23 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 1,450 | $8.04 | $11.7K | Form 4 |
| 2026-06-10 | Doyle Mittie | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 1,084 | $13.10 | $14.2K | Form 4 |
| 2026-06-10 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 138 | $13.10 | $1.8K | Form 4 |
| 2026-06-10 | VARKI PAUL | Officer (Chief Legal Officer) | Shares withheld for taxes / exercise cost | 1,081 | $13.10 | $14.2K | Form 4 |
| 2026-06-10 | Riley Jennifer | Officer (Chief Strategy Officer) | Shares withheld for taxes / exercise cost | 588 | $13.10 | $7.7K | Form 4 |
| 2026-06-02 | Jain Rita | Director | Grant / award / vesting (derivative) | 20,100 | — | $0 | Form 4 |
| 2026-06-02 | Heffernan Michael Thomas | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-02 | KANTOFF AARON | Director | Grant / award / vesting (derivative) | 20,100 | — | $0 | Form 4 |
| 2026-06-02 | KAPLAN GILLA | Director | Grant / award / vesting (derivative) | 20,100 | — | $0 | Form 4 |
| 2026-06-02 | Truex Samantha | Director | Grant / award / vesting (derivative) | 20,100 | — | $0 | Form 4 |
| 2026-06-02 | Lind Kevin Robert | Director | Grant / award / vesting (derivative) | 20,100 | — | $0 | Form 4 |
| 2026-05-28 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 679 | — | $0 | Form 4 |
| 2026-05-28 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 679 | $16.00 | $10.9K | Form 4 |
| 2026-05-28 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 679 | $8.04 | $5.5K | Form 4 |
| 2026-05-21 | NEIL GARRY ARTHUR | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 100,200 | — | $0 | Form 4 |
| 2026-05-21 | Doyle Mittie | Officer (Chief Medical Officer) | Grant / award / vesting | 43,500 | — | $0 | Form 4 |
| 2026-05-21 | VARKI PAUL | Officer (Chief Legal Officer) | Grant / award / vesting | 24,300 | — | $0 | Form 4 |
| 2026-05-21 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Grant / award / vesting | 39,900 | — | $0 | Form 4 |
| 2026-05-21 | Riley Jennifer | Officer (Chief Strategy Officer) | Grant / award / vesting | 34,200 | — | $0 | Form 4 |
| 2026-05-15 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-05-15 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 3,000 | $18.76 | $56.3K | Form 4 |
| 2026-05-15 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 3,000 | $12.65 | $38.0K | Form 4 |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 18,606 | — | $0 | Form 4 |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 18,606 | $24.12 | $448.8K | Form 4 |
| 2026-05-07 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion | 18,606 | $9.88 | $183.8K | Form 4 |
| 2026-05-06 | Chan Mitchell | Director | Open-market sale | 3,167 | $22.88 | $72.5K | Form 4 |
| 2026-05-06 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 28,650 | — | $0 | Form 4 |
| 2026-05-06 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 77,905 | — | $0 | Form 4 |
| 2026-05-06 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 10,058 | $22.88 | $230.1K | Form 4 |
| 2026-05-06 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 19,015 | $22.41 | $426.1K | Form 4 |
| 2026-05-06 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 44,944 | $21.20 | $952.7K | Form 4 |
| 2026-05-06 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 5,000 | $19.65 | $98.3K | Form 4 |
| 2026-05-06 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 27,538 | $18.03 | $496.4K | Form 4 |
| 2026-05-06 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 28,650 | $8.04 | $230.3K | Form 4 |
| 2026-05-06 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 77,905 | $12.65 | $985.5K | Form 4 |
| 2026-05-06 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 47,000 | — | $0 | Form 4 |
| 2026-05-06 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 8,900 | $22.57 | $200.9K | Form 4 |
| 2026-05-06 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 9,219 | $21.37 | $197.0K | Form 4 |
| 2026-05-06 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 2,700 | $20.76 | $56.1K | Form 4 |
| 2026-05-06 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 12,347 | $19.28 | $238.1K | Form 4 |
| 2026-05-06 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 13,834 | $18.55 | $256.7K | Form 4 |
| 2026-05-06 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Option exercise / conversion | 47,000 | $8.04 | $377.9K | Form 4 |
| 2026-05-06 | VARKI PAUL | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 12,563 | — | $0 | Form 4 |
| 2026-05-06 | VARKI PAUL | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 62,500 | — | $0 | Form 4 |
| 2026-05-06 | VARKI PAUL | Officer (Chief Legal Officer) | Open-market sale | 400 | $23.71 | $9.5K | Form 4 |
| 2026-05-06 | VARKI PAUL | Officer (Chief Legal Officer) | Open-market sale | 9,253 | $22.70 | $210.0K | Form 4 |
| 2026-05-06 | VARKI PAUL | Officer (Chief Legal Officer) | Open-market sale | 22,839 | $21.22 | $484.5K | Form 4 |
| 2026-05-06 | VARKI PAUL | Officer (Chief Legal Officer) | Open-market sale | 5,196 | $19.78 | $102.8K | Form 4 |
| 2026-05-06 | VARKI PAUL | Officer (Chief Legal Officer) | Open-market sale | 37,375 | $18.91 | $706.8K | Form 4 |
| 2026-05-06 | VARKI PAUL | Officer (Chief Legal Officer) | Option exercise / conversion | 12,563 | $8.04 | $101.0K | Form 4 |
| 2026-05-06 | VARKI PAUL | Officer (Chief Legal Officer) | Option exercise / conversion | 62,500 | $13.43 | $839.4K | Form 4 |
| 2026-05-05 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 679 | — | $0 | Form 4 |
| 2026-05-05 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-05-05 | Doyle Mittie | Officer (Chief Medical Officer) | Open-market sale | 1,679 | $16.00 | $26.9K | Form 4 |
| 2026-05-05 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 679 | $8.04 | $5.5K | Form 4 |
| 2026-05-05 | Doyle Mittie | Officer (Chief Medical Officer) | Option exercise / conversion | 1,000 | $12.65 | $12.7K | Form 4 |
| 2026-04-30 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 8,457 | $13.23 | $111.9K | Form 4 |
| 2026-04-29 | Sullivan Christopher Ryan | Officer (Chief Financial Officer) | Open-market sale | 8,458 | $13.09 | $110.7K | Form 4 |
Ask the chat about AVTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AVALO THERAPEUTICS INC (AVTX).
Last updated 2026-09-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.